Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › febuxostat

febuxostat

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of febuxostat

26 trials tracked of febuxostat: 16 in phase 3 or 4 and 6 with published results. The most-cited published study has 888 citations.

26Trials tracked
16Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 10 Phase 2 9 Other / NA 1
  1. Phase 3 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed · 888 cited
  2. Phase 3 Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat Completed · 151 cited
  3. Phase 4 Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion Completed · 83 cited
  4. Phase 4 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Completed · 26 cited
  5. Phase 4 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed · 15 cited
  6. Phase 4 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed · 2 cited
Show 20 more trials
  1. Phase 4 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed
  2. Phase 4 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed
  3. Phase 3 Lesinurad and Febuxostat Combination Extension Study in Gout Completed
  4. Phase 3 A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout Completed
  5. Phase 3 Safety and Efficacy of Oral Febuxostat in Subjects With Gout Completed
  6. Phase 3 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Completed
  7. Phase 3 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed
  8. Phase 3 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed
  9. Phase 3 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies Completed
  10. Phase 3 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Completed
  11. Phase 2 A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA Completed
  12. Phase 2 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones Completed
  13. Phase 2 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout Completed
  14. Phase 2 Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment Completed
  15. Phase 2 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout Completed
  16. Phase 2 Effect of Febuxostat on Blood Pressure Completed
  17. Phase 2 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout Completed
  18. Phase 2 Long-Term Safety of Febuxostat in Subjects With Gout. Completed
  19. Phase 2 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares Completed
  20. N/A Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Treat-to-target strategy improves gout remission vs symptom-driven care
Rheumatology RCT
Treat-to-target strategy improves gout remission vs symptom-driven care A new gout treatment strategy is changing outcomes
This open-label RCT in 308 adults with gout and hyperuricaemia found that a treat-to-target strategy (urate-guided titration) led to higher …
Many people with gout stay in pain despite treatment, but aiming for a specific uric acid level nearly doubles the chance of remission.
May 3, 2026
Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCT
Rheumatology RCT
Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCT Gout study finds combination treatment reduces flares but not urate levels
A 24-week RCT in 348 primary gout patients found adding activated charcoal to febuxostat 20 mg did not improve serum urate control versus fe…
Adding activated charcoal to gout medication reduced painful flares and cholesterol, but failed to lower urate levels better than standard t…
Apr 4, 2026